BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 22278419)

  • 21. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
    Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
    Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
    Younes MN; Yigitbasi OG; Park YW; Kim SJ; Jasser SA; Hawthorne VS; Yazici YD; Mandal M; Bekele BN; Bucana CD; Fidler IJ; Myers JN
    Cancer Res; 2005 Jun; 65(11):4716-27. PubMed ID: 15930290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
    Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
    Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
    Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.
    Bauer AJ; Terrell R; Doniparthi NK; Patel A; Tuttle RM; Saji M; Ringel MD; Francis GL
    Thyroid; 2002 Nov; 12(11):953-61. PubMed ID: 12490072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
    Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
    Sini P; Wyder L; Schnell C; O'Reilly T; Littlewood A; Brandt R; Hynes NE; Wood J
    Clin Cancer Res; 2005 Jun; 11(12):4521-32. PubMed ID: 15958638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F
    J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma.
    Ye C; Feng C; Wang S; Liu X; Lin Y; Li M
    Endocrinology; 2002 Sep; 143(9):3522-8. PubMed ID: 12193566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
    Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
    Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.
    Xu HY; Pan YM; Chen ZW; Lin Y; Wang LH; Chen YH; Jie TT; Lu YY; Liu JC
    J Ethnopharmacol; 2013 Apr; 146(3):724-33. PubMed ID: 23434607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas.
    Li Y; Fu SY; Wang LH; Wang FY; Wang NN; Cao Q; Wang YT; Yang JY; Wu CF
    Cancer Lett; 2015 Dec; 369(1):86-96. PubMed ID: 26254539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.